Torpdemant9789

Reading fluency is essential for our functioning in the literate society in which we live. Reading expressiveness or prosody, along with speed and accuracy, are considered key aspects of fluent reading. Prosodic patterns may vary, not being the same in children learning to read as in adulthood. But little is known about the prosodic characteristics and reading fluency of people with neurodegenerative diseases that causes language impairment and reading difficul- ties, such as Alzheimer's disease (AD).

The aim of this work was to study reading fluency in AD, considering reading speed, ac- curacy and reading prosody.

The participants were 20 healthy elderly Spanish adults, and 20 AD patients, aged 64-88 years. An experimental text was designed, that included declarative, exclamatory, and interrogative sentences, words with different stresses and low-frequency words. The reading of the participants was recorded and analyzed using Praat software.

The AD group showed significantly longer reading duration, both at the syllable level and at the word and sentence level. Veliparib inhibitor These patients also committed more pauses between words, which were also longer, and more reading errors. The control group showed a variation of the syllabic F0 in the three types of sentences, while these variations only appeared in declarative ones in the AD group.

The pauses, along with the slight pitch variations and the longer reading times and er- rors committed, compromise the reading fluency of people with AD. Assessment of this reading feature could be interesting as a possible diagnostic marker for the disease.Recent Advances in Anti-Infective Drug Discovery.

The pauses, along with the slight pitch variations and the longer reading times and er- rors committed, compromise the reading fluency of people with AD. Assessment of this reading feature could be interesting as a possible diagnostic marker for the disease.Recent Advances in Anti-Infective Drug Discovery.

Research has documented the stigma that individuals with degenerative neurological diseases experience, but caregivers also experience stigma by associa- tion (i.e., affiliate stigma). In order to shed light on the stigma of caregivers of people with degener- ative neurological diseases, the current study aimed to explore cross-cultural differences in the pre- valence of Parkinson's disease (PD) caregiver affiliate stigma, as well as the relationship between PD symptoms and caregiver affiliate stigma. Applications for Alzheimer's disease are discussed.

Survey data were collected in PD clinics at public, academic medical centers. Informal caregivers of an individual with PD from the US (n = 105) and from Mexico (n = 148) participated in the study. Caregivers completed a questionnaire that included the MDS Unified PD Rating Scale to describe the symptoms of the individual with PD, as well as the Affiliate Stigma Scale and demo- graphic information.

A series of multiple regressions was run to examine whethnerative diseases are related to affiliate stig- ma experienced by caregivers, and these relationships may differ cross-culturally. Negative public attitudes concerning bowl and bladder issues and the physical symptoms that accompany PD re- main a source of stigma for caregivers and families, particularly in the US. Interventions for care- givers of individuals with neurodegenerative diseases should include strategies for coping with stig- ma concerning bladder and bowel problems, as well as other physical and mental health issues.Recent Advances in Anti-Infective Drug Discovery.

Alzheimer's disease (AD) is the most common form of neurodegenerative disorder characterized by cognitive impairment, which represents an urgent public health concern. Given the worldwide impact of AD, there is a compelling need for effective therapies to slow down or halt this disorder.

Choline alphoscerate (α-GPC) represents a potentially effective cholinergic neurotrans- mission enhancing agent with an interesting clinical profile in cognitive dysfunctions improve- ment, although only scanty data are available about the mechanisms underlying such beneficial ef- fects.

The SH-SY5Y neuronal cell line, differentiated for 1 week with 10 μm of all-trans-reti- noic acid (RA), to achieve a switch towards a cholinergic phenotype, was used as an in vitro model of AD. SH-SY5Y cells were pre-treated for 1h with α-GPC (100nM) and treated for 72 h with Aβ25-35 (10μM).

α-GPC was able to antagonize Aβ25-35 mediated neurotoxicity and attenuate the Aβ-in- duced phosphorylation of the Tau protein. Moreover, α-GPC exbasis for innovative therapy.Recent Advances in Anti-Infective Drug Discovery.

Alzheimer's disease with a causative genetic mutation (AD-CGM) is an un- common form, characterized by a heterogeneous clinical phenotype and variations in the genotype of racial groups affected.

We aimed to systemically describe the phenotype variance and mutation spectrum in the large sample size of the Peking Union Medical College Hospital (PUMCH) cohort, Beijing, China.

Next-generation sequencing (NGS) was carried out in 1108 patients diagnosed with dementia. A total of 40 Han Chinese patients with three AD gene mutations were enrolled. A systemic review of all the patients was performed, including clinical history, neurocognitive assessment, brain magnetic resonance imaging, and cerebrospinal fluid (CSF) biomarkers.

We studied the following gene mutation variants 12 AβPP, 13 PSEN1, and 9 PSEN2, and 23 among them were novel. Most of them were early-onset, but PSEN1 mutation carriers had the youngest onset age. The commonest symptoms were similar to those of AD, including an amnestic syndrome, folld complete screening of genetic mutations using NGS. Although family history was usually present, we found non-familial cases of all three genetic mutations.Recent Advances in Anti-Infective Drug Discovery.

Micro-RNAs (miRNA) belong to the substantial class of post-transcriptional gene regulators with decisive functions in typical cellular and disease progressions. They are short RNA molecules that are not translated into proteins, bind to the complementary sites of various mRNAs, blocking them, and hence lead to translational inhibition.

These miRNA molecules act as signatory molecules or biomarkers for various types of malignancies. Different miRNAs are involved in different cancer-linked pathways depending on the nature, stage, and kind of cancer. The objective of this article is to discuss and review the role and significance of various miRNAs in two of the most prominent cancers; breast and ovarian cancer.

The role and participation of miRNAs in instigation, propagation, and metastasis of melanoma is elucidated.

This article focuses on the up and downregulation of various miRNAs in breast and ovarian cancer, with stress on diversity in their occurrence and specificity in their threshold levels in certain types and stages of cancer, suggesting their potential role as an effective diagnostic and treatment tool for cancer.